Lymphoma News

Certain individuals with non-cell lung cancer who experienced immune-related adverse events due to immune checkpoint inhibitor therapy had improved survival outcomes, according to retrospective study data published in JAMA Network Open.

AI could have the ability to answer some patient questions on cancer instead of clinicians, reducing clinician burdens and improving access to care, according to study results published in JAMA Oncology.

The FDA granted accelerated approval to lisocabtagene maraleucel for treatment of adults with relapsed or refractory follicular lymphoma who received at least two prior lines of systemic therapy.

The gap in cancer mortality between Black and white individuals shrunk dramatically during the past 3 decades, according to a new report.

As part of routine screening for financial hardship, clinicians should discuss an individual’s employment, access to paid leave and health insurance coverage when constructing a treatment plan relating to cancer care.

Allen S. Ho, MD, did not wait to promote active surveillance when he started practicing medicine a decade ago.

The addition of acalabrutinib to standard-of-care chemoimmunotherapy significantly extended PFS compared with standard therapy alone in a randomized study, according to press release the agent’s manufacturer.

More than 20% of patients with cancer participate in some form of clinical study, and that number is considered a “floor” estimate, according to study results published in Journal of Clinical Oncology.

New guidelines for vaccinating adults with solid or hematologic cancers detailed the importance of vaccination optimization, multidisciplinary coordination and vaccination of household members.

Two blood biomarkers — pre-lymphodepletion C-reactive protein and ferritin — may help predict which patients with lymphoma are at risk for poor outcomes after chimeric antigen receptor T-cell therapy.